The present disclosure provides a suspension-type
eye drop having excellent redispersibility. More specifically, the present disclosure provides an aqueous-based suspension formulation containing a first component and a second component wherein the first component is (E)-2-(7-trifluoromethylchroman-4-
subunit)-N-(7-hydroxy-5, 6, 7, 8-tetrahydronaphthalene-1-yl)
acetamide, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof. And the second component comprises at least one component selected from the group consisting of diquafosol, cyclosporin,
hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof.